Netherlands: These 7 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

DrugPatentWatch^® Estimated Loss of Exclusivity Dates in Netherlands

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

Summary: Netherlands: These 7 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

Subscribe to access the full database, or Start Trial
Tradename	Ingredient	Estimated Entry Opportunity Date
XENLETA	lefamulin acetate	2027-03-20
XERMELO	telotristat etiprate	2026-12-12
TEPMETKO	tepotinib hydrochloride	2027-07-12
TYMLOS	abaloparatide	2026-10-03
ZYKADIA	ceritinib	2026-12-08
>Tradename	>Ingredient	>Estimated Entry Opportunity Date

Details: Netherlands: These 7 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

When can XENLETA (lefamulin acetate) generic drug versions launch?

Generic name: lefamulin acetate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 20, 2027
Generic Entry Controlled by: Netherlands Patent 301,086

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug.

This drug has one hundred and twenty patent family members in thirty-six countries. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. One supplier is listed for this generic product. Additional details are available on the lefamulin acetate profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch?

Generic name: telotristat etiprate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 12, 2026
Generic Entry Controlled by: Netherlands Patent 300,929

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

This drug has seventy patent family members in twenty-nine countries.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. One supplier is listed for this generic product. Additional details are available on the telotristat etiprate profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch?

Generic name: tepotinib hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: Netherlands Patent 301,176

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug.

This drug has eighty patent family members in thirty-seven countries. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tepotinib hydrochloride profile page.

When can TYMLOS (abaloparatide) generic drug versions launch?

Generic name: abaloparatide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 03, 2026
Generic Entry Controlled by: Netherlands Patent 301,235

TYMLOS is a drug marketed by Radius. There are nine patents protecting this drug.

This drug has fifty-six patent family members in twenty-nine countries. There has been litigation on patents covering TYMLOS

See drug price trends for TYMLOS.

The generic ingredient in TYMLOS is abaloparatide. One supplier is listed for this generic product. Additional details are available on the abaloparatide profile page.

When can ZYKADIA (ceritinib) generic drug versions launch?

Generic name: ceritinib
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 08, 2026
Generic Entry Controlled by: Netherlands Patent 300,763

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

This drug has three hundred and twenty-two patent family members in fifty-six countries.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ceritinib profile page.

When can MULPLETA (lusutrombopag) generic drug versions launch?

Generic name: lusutrombopag
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 31, 2027
Generic Entry Controlled by: Netherlands Patent 300,998

MULPLETA is a drug marketed by Vancocin Italia. There are three patents protecting this drug.

This drug has forty-one patent family members in twenty countries.

See drug price trends for MULPLETA.

The generic ingredient in MULPLETA is lusutrombopag. Three suppliers are listed for this generic product. Additional details are available on the lusutrombopag profile page.

When can WINLEVI (clascoterone) generic drug versions launch?

Generic name: clascoterone
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 03, 2027
Generic Entry Controlled by: Netherlands Patent 301,358

WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug.

This drug has ninety-four patent family members in thirty countries. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. One supplier is listed for this generic product. Additional details are available on the clascoterone profile page.